Entrada Therapeutics Inc Total Assets
Entrada Therapeutics Inc total assets. Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) holds total assets worth $298.88 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Entrada Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of Entrada Therapeutics Inc (2019–2025)
Total assets of Entrada Therapeutics Inc from 2019 to 2025. This chart illustrates how Entrada Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Entrada Therapeutics Inc stock price for real-time trading data and today's change.
Entrada Therapeutics Inc - Asset Composition Analysis
Entrada Therapeutics Inc Total Assets Breakdown (December 2025)
Entrada Therapeutics Inc total assets breakdown as of December 2025. Entrada Therapeutics Inc's total assets of $298.88 Million consist of 81.2% current assets and 18.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.0% |
| Accounts Receivable | $2.58 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Entrada Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Entrada Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entrada Therapeutics Inc's current assets represent 81.2% of total assets in 2025, a decrease from 95.6% in 2019.
- Cash Position: Cash and equivalents constituted 24.0% of total assets in 2025, down from 92.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Entrada Therapeutics Inc Competitors by Total Assets
Key competitors of Entrada Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Entrada Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.89 | 18.64 | 17.26 |
| Quick Ratio | 10.89 | 18.64 | 17.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $211.33 Million | $349.34 Million | $116.37 Million |
Entrada Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Entrada Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -28.3% |
| Total Assets | $377.38 Million |
| Market Capitalization | $190.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Entrada Therapeutics Inc's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Entrada Therapeutics Inc's assets decreased by 28.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Entrada Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Entrada Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $377.38 Million | -28.30% |
| 2024-12-31 | $526.32 Million | +12.18% |
| 2023-12-31 | $469.19 Million | +86.15% |
| 2022-12-31 | $252.06 Million | -17.58% |
| 2021-12-31 | $305.83 Million | +602.63% |
| 2020-12-31 | $43.53 Million | +138.66% |
| 2019-12-31 | $18.24 Million | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potent… Read more